Clinical Trial

Cancer Survivors Program

Study acronym: SURV-QoL
Recruiting
View on ClinicalTrials.gov →
Summary
The questionnaire for assessment of adverse events after completion of cancer treatment, which is being piloted at the Masaryk Memorial Cancer Institute, aims to detect a wide range of adverse effects early on, thus facilitating adequate intervention and planning of follow-up care for all cancer survivors.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-05-05 -> 2026-09-05 2026-06-12
Trial Details
NCT Number NCT07253987
Lead Sponsor Masaryk Memorial Cancer Institute
Conditions Prostate Cancer Patients, Breast Cancer Patients
Enrollment 200 participants
Start Date 2025-05-05
Primary Completion 2026-09-05 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-11